Escalating Doses of Donor Lymphocytes for Incipient Graft Rejection Following SCT for Thalassemia

Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2009.298
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Escalating-Dose HLA-mismatched DLI Is Safe for the Treatment of Leukaemia Relapse Following Alemtuzumab-Based Myeloablative Allo-SCT

Bone Marrow Transplantation
TransplantationHematology
2013English

Salvage Allogeneic Hematopoietic SCT for Primary Graft Failure in Children

Bone Marrow Transplantation
TransplantationHematology
2013English

Corneal Graft Rejection 10 Years After Penetrating Keratoplasty in the Cornea Donor Study

Cornea
Ophthalmology
2014English

Second Marrow Transplants for Graft Failure in Patients With Thalassemia

Bone Marrow Transplantation
TransplantationHematology
1999English

Reply To: Mounting Evidence Indicates That Escalating Doses of Allopurinol Are Unnecessary for Cardiovascular Protection

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2018English

Importance of Blood Graft Characteristics in Auto-Sct: Implications for Optimizing Mobilization Regimens

Bone Marrow Transplantation
TransplantationHematology
2011English

Corneal Graft Rejection After Keratoplasty

Oftalmologiya
Ophthalmology
2017English

Influence of Various Donor-Related Factors on Ultimate Graft Survival Following Penetrating Keratoplasty

Journal of Evolution of Medical and Dental Sciences
2017English

The Number of Donor-Specific IL-21 Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection

Frontiers in Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy